Lexeo Therapeutics, Inc. Common Stock (LXEO) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

27/ 100

GoAI Score

Sell

Valuation

29

Expensive

Sentiment

43

Mixed

Risk

72

High Risk

Momentum

26

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: R. Nolan Townsend
Listed since: Nov 3, 2023
Employees: 63

Market position

Day range

Current $3.21

$3.115$3.28

52-week range

Current $3.21

$2.98$10.99

Open: $3.27
Previous close: $3.31
Volume: 2.55M; 2.31× average
Average volume: 1.1M; Average daily volume
Market cap: 252.05M USD
Beta: 1.64; Market reference 1
50-day average: $4.352; -26.24% below average
200-day average: $5.7832; -44.49% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 477.58M USD
P/E (TTM): -2.79×
P/B (TTM): 1.17×
P/S (TTM): 0×
EV / EBITDA: -4.89×
Earnings yield: -18.77%
Free cash flow yield: -18.58%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -40.52%
Return on assets: -37.20%
Return on invested capital: -42.92%

Financial health

Debt / equity: 0.03×
Current ratio: 11.21×
Altman Z-score: 5.34
Piotroski F-score: 1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

654K USD-60.53%

Operating income

−109.26M USD-3.30%

Net income

−99.96M USD-1.66%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	—	—	654K USD	1.66M USD
Gross profit	—	—	—	654K USD	1.66M USD
Research and development	63.8M USD	74.09M USD	53.13M USD	49.16M USD	45.12M USD
Selling, general, and administrative	45.46M USD	31.68M USD	15.38M USD	12M USD	7.17M USD
Operating expenses	109.26M USD	105.77M USD	68.51M USD	61.16M USD	52.29M USD
Interest income	6.13M USD	7.56M USD	2.87M USD	1.33M USD	15K USD
Interest expense	206K USD	114K USD	205K USD	91K USD	—
Depreciation and amortization	2.08M USD	2M USD	1.84M USD	1.15M USD	13K USD
Operating income	−109.26M USD	−105.77M USD	−68.51M USD	−60.51M USD	−50.64M USD
Net income	−99.96M USD	−98.33M USD	−66.39M USD	−59.28M USD	−50.62M USD

Company facts updated Oct 8, 2026.

Earnings

EPS beat rate: 55%; 6 beats, 4 misses, 1 met estimate
Average EPS surprise: +0.20%; 11 comparable reports
Latest EPS result: -0.3; Estimate -0.29 · Miss by 5.20%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$21.13

558.26% upside

Past 12 months12-month forecastHigh $30.00Average $21.13Low $10.00

Rating distribution

5 ratings

Strong buy00%

Buy5100%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

5 institutions

LXEO news

globenewswire.comOct 8, 2026

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will…

Read source

globenewswire.comOct 1, 2026

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI…

Read source

prnewswire.comSep 23, 2026

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a…

Read source

globenewswire.comSep 23, 2026

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will…

Read source

seekingalpha.comSep 22, 2026

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

Read source

globenewswire.comSep 22, 2026

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006…

Read source